You have 9 free searches left this month | to do more

zanubrutinib

Zanubrutinib is a drug used to treat Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, and other conditions. Zanubrutinib is being actively studied in 30 studies and prior, has been studied in 10.

Top SponsorsTop SitesTop Investigators
BeiGeneHenan Cancer HospitalJennifer R. Brown, MD, PhD
German CLL Study GroupJiangsu Province HospitalXiao-Jun Huang
Peking Union Medical College HospitalMD Anderson Cancer CenterYazeed Sawalha
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
P
Not yet recruiting
  • CNS Lymphoma
  • Zanubrutinib
  • (no location specified)
2021-11-02
Nov 2, 2021
Z
Recruiting
  • Antiphospholipid Syndrome
  • +2 more
  • zanubrutinib
  • Tianjin, Tianjin, China
  • +1 more
2022-01-19
Jan 19, 2022
B
Completed
  • Healthy
  • Male
  • Daytona Beach, Florida
    Covance Clinical Research Unit
2021-08-30
Aug 30, 2021
J
Not yet recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma
  • Boston, Massachusetts
  • +2 more
2021-12-09
Dec 9, 2021
B
Not yet recruiting
  • Relapsed/Refractory Marginal Zone Lymphoma
  • Zanubrutinib
  • +2 more
  • (no location specified)
2021-10-21
Oct 21, 2021
B
Recruiting
  • Lupus Nephritis
  • Zanubrutinib
  • Placebo
  • Guangdong, Guangzhou, China
    Guangdong General Hospital
2021-03-17
Mar 17, 2021
T
Recruiting
  • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
  • Zanubrutinib
  • +5 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
2021-04-12
Apr 12, 2021
R
Recruiting
  • Primary Mediastinal Large B Cell Lymphoma
  • EBV-Positive DLBCL, Nos
  • Shanghai, Shanghai, China
    Ruijin Hospital
2021-03-29
Mar 29, 2021
P
Recruiting
  • Primary Vitreoretinal Lymphoma
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
2021-05-19
May 19, 2021
H
Recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Zhengzhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
2020-12-29
Dec 29, 2020
B
Completed
  • B-cell Lymphoma
  • Zanubrutinib
  • Beijing, Beijing, China
  • +3 more
2021-09-26
Sep 26, 2021
B
Recruiting
  • B-cell Malignancies
  • Zanubrutinib
  • +4 more
  • Concord, New South Wales, Australia
  • +6 more
2020-12-15
Dec 15, 2020
M
Recruiting
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Rituximab
  • Zanubrutinib
  • Houston, Texas
    M D Anderson Cancer Center
2021-02-08
Feb 8, 2021
G
Recruiting
  • Richter Transformation
  • Tislelizumab
  • Zanubrutinib
  • Vienna, Austria
  • +11 more
2021-02-04
Feb 4, 2021
B
Recruiting
  • Mature B-cell Malignancies
  • Zanubrutinib
  • Nagoya, Aichi, Japan
  • +14 more
2021-02-18
Feb 18, 2021
B
Completed
  • Hepatic Insufficiency & Healthy Subjects
  • Zanubrutinib
  • Miami, Florida
  • +1 more
2020-04-22
Apr 22, 2020
B
No longer available
  • Waldenstr√∂m Macroglobulinemia
  • Zanubrutinib
  • Mobile, Alabama
  • +19 more
2021-06-08
Jun 8, 2021
B
Completed
  • COVID-19 Pulmonary Complications
  • COVID-19
  • Zanubrutinib
  • +2 more
  • Scottsdale, Arizona
  • +17 more
2021-06-15
Jun 15, 2021
B
Recruiting
  • Chronic Lymphocytic Leukemia
  • +8 more
  • Adelaide, Australia
  • +6 more
2021-11-29
Nov 29, 2021
B
Not yet recruiting
  • Relapsed Diffuse Large B-cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • Zanubrutinib
  • Hefei, Anhui, China
  • +21 more
2021-09-27
Sep 27, 2021
Y
Suspended
  • Diffuse Large B-Cell Lymphoma
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2021-10-05
Oct 5, 2021
B
Completed
  • Diffuse Large B-cell Lymphoma
  • Zanubrutinib
  • Beijing, Beijing, China
  • +10 more
2021-10-11
Oct 11, 2021
B
Active, not recruiting
  • Marginal Zone Lymphoma
  • Zanubrutinib
  • Lake Success, New York
  • +28 more
2021-05-18
May 18, 2021
T
Not yet recruiting
  • Non Hodgkin Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib
  • +6 more
  • Nanjin, Jiangsu, China
    Department of Haematology, the First Affiliated Hospital of Nanj
2022-01-19
Jan 19, 2022